Avastin gains accelerated approval for breast cancer
Genetech's Avastin (bevacizumab) gains accelerated approval Feb. 22 for first-line treatment of metastatic HER-2 negative breast cancer, in combination with paclitaxel. Based on progression-free survival, the approval follows a mixed vote from the Oncologic Drugs Advisory Committee (1"The Pink Sheet," Dec. 17, 2007, p. 15). Visit 2www.ThePinkSheetDAILY.com for coverage of the late-breaking approval. To sign up for a free trial, visit our website or call 800-332-2181...
You may also be interested in...
While the Oncologic Drugs Advisory Committee generally endorses the idea that progression-free survival can support full approval of first-line therapies in metastatic breast cancer, the panel left FDA with the challenge of qualifying how PFS represents clinical benefit and determining the measure's meaningfulness for regulatory purposes
Robust natural history data sets with well-chosen outcomes are fundamental in Aetion’s regulatory feasibility tool for real-world evidence, built through analysis of US FDA case studies and guidance.
Ideally, the studies would be underway at the time of approval, as the US FDA’s new authority allows, but Office of Therapeutic Products Director Nicole Verdun sys there will be exceptions.